Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous disease. Response durability up to 1.5 y followin...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Hum Vaccin Immunother
Главные авторы: Bhuyan, Prakash K., Dallas, Michael, Kraynyak, Kim, Herring, Timothy, Morrow, Matthew, Boyer, Jean, Duff, Susan, Kim, Joseph, Weiner, David B.
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2020
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078703/
https://ncbi.nlm.nih.gov/pubmed/33175656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1823778
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы